From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Whilst I wait for Dame Emma and her GSK plc conference call, thoughts on the continued Aston Martin Lagonda comedy and Next plc commonsense

By Chris Bailey | Wednesday 2 November 2022


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I always analytically like the pharmaceutical sector, even if I am not enough of a sector geek to be a massive expert. It is getting close to two years since I bought GSK plc (GSK) shares for the first time in a couple of decades. It gave a solid Q3 set of numbers earlier today, talking about “2022 Guidance raised…(as it) expect to deliver growth in sales of between 8%-10% CER and growth in 2022 adjusted operating profit of between 15%-17% CER". It is always better to raise numbers than not, but that does not mean that the management, led by the extremely well remunerated Dame Emma, does not still have a bunch of questions to answer.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 16:13:48